Advances in SPECT and PET for the management of heart failure

Heart

Volumn 96, Issue 23, 2010, Pages 1932-1937

  Camici, Paolo G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN;

AUTONOMIC DYSFUNCTION; DENSITY; HEART FAILURE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; ISCHEMIC HEART DISEASE; MICROVASCULARIZATION; MYOCARDIAL HIBERNATION; PATIENT SATISFACTION; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CORONARY DISEASE; HEART FAILURE; HUMANS; MICROCIRCULATION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78649929057     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.184374     Document Type: Review

References (25)

1. Mehta PA, Dubrey SW, McIntyre HF, et al. Mode of death in patients with newly diagnosed heart failure in the general population. Eur J Heart Fail 2008;10:1108-16.
2. Dickstein K, Cohen-Solal A, Filippatos G, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-42.
3. Caldwell JH, Link JM, Levy WC, et al. Evidence for pre- to postsynaptic mismatch of the cardiac sympathetic nervous system in ischemic congestive heart failure. J Nucl Med 2008;49:234-41. This review article describes the main mechanisms of autonomic dysfunction in ischaemic congestive heart failure. In particular, the authors provide evidence for preto post-synaptic mismatch of the cardiac sympathetic nervous system.
4. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7. This is one of the first studies reporting the prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.
5. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23.
6. Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-66.
7. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579-90.
8. Kyuma M, Nakata T, Hashimoto A, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 2004;45:155-63.
9. Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46. This article reports the results of a retrospective European multicentre study with metaiodobenzylguanidine myocardial imaging for assessment of risk for major cardiac events in a rather large cohort of heart failure patients.
10. Verberne HJ, Brewster LM, Somsen GA, et al. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008;29:1147-59.
11. Merlet P, Delforge J, Syrota A, et al. Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 1993;87:1169-78.
12. Spyrou N, Rosen SD, Fath-Ordoubadi F, et al. Myocardial beta-adrenoceptor density 1 month after acute myocardial infarction predicts left ventricular volumes at six months. J Am Coll Cardiol 2002;40:1216-24. This is the first study to demonstrate that myocardial b-adrenoceptor density measured with PET 1 month after acute myocardial infarction predicts left ventricular remodelling at 6 month follow-up.
13. Gaemperli O, Liga R, Spyrou N, et al. Myocardial b-adrenoceptor density early after infarction predicts long term incidence of congestive heart failure. Eur Heart J 2010;31:1722-9.
14. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-40. This is a comprehensive review which describes the mechanisms of coronary microvascular dysfunction in different cardiac disorders. The article also provides a useful clinical and pathogenetic classification of coronary microvascular dysfunction.
15. Camici PG, Rimoldi OE. The clinical value of myocardial blood flow measurement. J Nucl Med 2009;50:1076-87.
16. Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35. This paper demonstrates the usefulness of measuring absolute myocardial blood flow with PET in patients with hypertrophic cardiomyopathy. The results of the study provide evidence that the severity of coronary microvascular dysfunction is predictive of unfavourable outcome in these patients.
17. Maron MS, Olivotto I, Maron BJ, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:866-75.
18. Yoshinaga K, Chow BJ, Williams K, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol 2006;48:1029-39.
19. Herzog BA, Husmann L, Valenta I, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009;54:150-6. This paper demonstrates the usefulness of measuring absolute myocardial blood flow with PET in patients with ischaemic heart disease.
20. Carrio I, Cowie MR, Yamazaki J, et al. Cardiac sympathetic imaging with mIBG in heart failure. J Am Coll Cardiol Cardiovasc Im 2010;3:92-100.
21. Kasama S, Toyama T, Sumino H, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 2008;49:907-14.
22. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008;117:103-14.
23. Tarakji KG, Brunken R, McCarthy PM, et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006;113:230-7.
24. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002-12.
25. D'Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009;2:1060-8. This study provides evidence that the prognostic benefit obtained from coronary revascularisation in patients with ischaemic heart failure correlates with the amount of hibernating myocardium.